Abolis Biotechnologies has launched Microbial Intelligence Explorer (MINE), a data platform designed to compress the discovery timeline for microbial-derived cosmetic ingredients.

The French biotech firm, founded in 2014, said MINE connects multi-omics data — layered biological datasets that combine genomics, metabolomics and related fields — with experimental and industrial insight so R&D teams can decide which microbial signals warrant further testing.

Sylvia Julien, General Manager of the MINE Business Unit, framed the problem the platform targets. "The challenge in microbial biotechnologies lies in the difficulty of integrating the various pieces of information and, therefore, to know which signals matter and which hypotheses deserve further testing for product development," she said.

What does MINE actually change for formulators?

For cosmetic manufacturers, the bottleneck is rarely a lack of microbial candidates. It is the time and specialist expertise needed to map which strains produce which molecules, and which metabolic routes justify industrial investment. MINE aims to remove that filter step by making genomic and multi-omics outputs interpretable without requiring every decision maker to hold an omics or bioinformatics degree.

The platform allows users to:

• Examine how individual strains contribute to producing molecules of interest
• Map interactions inside more complex microbial systems
• Connect biological evidence with validation, process development and scale-up work

Where did the platform come from?

MINE evolved from Microbiome Studio, a machine learning-enabled analytical tool developed under Metapath, an industrial programme supported by the French government. Abolis originally built Microbiome Studio for in-house microbial biotechnology programmes and refined it through industrial collaborations before commercialising the architecture as MINE for external R&D and open innovation teams.

Why is Abolis pushing microbial ingredients now?

Supply chain resilience, regulatory pressure on ingredient provenance, and demand for bio-based alternatives have put microbial fermentation back on procurement agendas across personal care. Microbial routes also offer access to molecules that are difficult or unsustainable to source through plant extraction or chemical synthesis.

"MINE software release marks the point at which more than a decade of microbial biotechnology, data and industrial experience of Abolis becomes a platform to boost partners' research and our own research," said Cyrille Pauthenier, co-founder and CEO of Abolis Biotechnologies. "It strengthens Abolis' ability to support decisions before, during and beyond experimentation, connecting biological evidence with the realities of validation, process development and scale-up."

What does this mean for ingredient procurement?

For buyers, the practical question is throughput from lab to commercial-scale ingredient. MINE does not replace fermentation capacity, regulatory dossiers or safety data. It compresses the upstream decision cycle that decides which programmes reach those stages, shortening the lead time between a strain identified in silico and a candidate on a formulator's bench.

What to watch next

Abolis has not disclosed pricing, a partner list or a public user pipeline. The next data point to track is whether the first external partner programmes using MINE produce published ingredient launches, INCI filings or process patents within 12 to 18 months — a signal of whether the platform is shortening industrial timelines or simply reorganising existing ones.